Skip to main content
. 2017 Aug 15;18:268. doi: 10.1186/s12882-017-0686-3

Fig. 3.

Fig. 3

Effect of tolvaptan 60 mg on p-AVP at baseline, during and after NO inhibition in ADPKD. Data are given as median with 25th and 75th percentiles. Wilcoxon’s signed rank test used for comparison between treatment groups prior to L-NMMA infusion, at the end of L-NMMA infusion and 1 h after the end of L-NMMA infusion